Lifevantage Corp - LFVN STOCK NEWS

LifeVantage Corporation (Nasdaq: LFVN) recently launched the innovative Evolve Compensation Plan, celebrating a successful first month across the U.S., Japan, and Australia. This new plan aims to enhance business-building behaviors among Consultants. Key appointments include Michael Allen as President of LifeVantage Japan and Allana Hinks as General Manager of Australia and New Zealand. The TrueScience® Liquid Collagen product, launched in early March 2023, has already seen significant success, increasing monthly skin care revenue by over 300% since its U.S. debut in June 2022. With this positive momentum, LifeVantage is focusing on geographic and product expansion, positioning itself for improved growth and profitability.

LifeVantage Corporation (Nasdaq: LFVN) has announced a $0.03 cash dividend per share, to be paid on March 15, 2023, for stockholders of record as of March 1, 2023. This dividend reflects the company’s commitment to returning value to shareholders while engaging in nutrigenomics research and product development. LifeVantage, a pioneer in the field, offers a range of dietary supplements and wellness products, including its flagship Protandim^® line. Forward-looking statements highlight future growth initiatives and the potential variability of dividends, urging investors to consider associated risks.

LifeVantage Corporation (LFVN) reported its second fiscal quarter results for 2023, revealing a revenue increase of 2.8% to $53.7 million. When adjusted for foreign currency fluctuations, revenue rose approximately 7.4%. The Americas saw a 14.4% revenue increase, while Asia/Pacific & Europe faced a 20.2% decline. The company reported a net loss of $1.1 million or $0.08 per diluted share, contrasting with a net income of $0.1 million from the previous year. Adjusted EBITDA was $0.8 million. Despite the challenges, the company maintains a strong balance sheet with $17.4 million in cash and no debt. Guidance for the fiscal year suggests revenues between $202 million and $212 million.

LifeVantage Corporation (Nasdaq: LFVN) will announce its financial results for the second quarter ended December 31, 2022, on February 2, 2023, after the market closes. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET). Interested parties can call (877) 704-4453 in the U.S. or (201) 389-0920 internationally to participate. A replay will be available until February 9, 2023. Additionally, a live webcast will be accessible on the company’s Investor Relations website and archived for 30 days.

LifeVantage Corporation (Nasdaq: LFVN) announced its strategic transformation initiative, LV360, aimed at enhancing the Consultant and Customer experience. Key features include the launch of Evolve, a new compensation model, and the Rewards Circle customer loyalty program, set to debut on March 1, 2023. Over 10,000 Consultants participated in the announcement via a global broadcast. The initiative aims to strengthen market position and address evolving consumer trends with new products, enhanced e-commerce, and extensive training sessions scheduled globally. The company's focus remains on solidifying its reputation in health and wellness.

LifeVantage Corporation (Nasdaq: LFVN) has declared a quarterly cash dividend of $0.03 per share, to be distributed on December 15, 2022, to shareholders on record as of December 1, 2022. This announcement reflects the company's commitment to providing returns to its investors amidst its focus on nutrigenomics and health solutions. LifeVantage markets a range of dietary supplements, including its flagship product Protandim^®, and is dedicated to research and development in natural health advancements.

LifeVantage Corporation (Nasdaq: LFVN) reported Q1 fiscal 2023 revenue of $51.8 million, a 2.7% decrease year-over-year. However, excluding foreign currency fluctuations, revenue grew 2.3%. Active accounts fell 6.7% to 153,000, with notable declines in the Americas (7.8%) and Asia/Pacific & Europe (4.1%). Net income was $0.6 million, or $0.05 per diluted share, down from $3.3 million, or $0.25 per share a year ago. The company maintains a solid balance sheet with $17.6 million cash and no debt. Fiscal 2023 guidance remains at $200-$212 million in revenue and adjusted EBITDA of $12-$14 million.

LifeVantage Corporation (Nasdaq: LFVN) will announce its Q1 financial results for the period ending September 30, 2022, on November 2, 2022, after market close. The company will host a conference call for investors at 2:30 p.m. MT (4:30 p.m. ET) on the same day. Interested parties can join the call via U.S. (855) 327-6837 or international (631) 891-4304. A replay will be available until November 9, 2022. Additionally, a live webcast will be accessible on their Investor Relations website, archived for 30 days.

LifeVantage Corporation (Nasdaq: LFVN) has announced a quarterly cash dividend of $0.03 per share, scheduled for payment on September 15, 2022, to stockholders on record as of September 2, 2022. This decision highlights the company's commitment to returning value to its shareholders. LifeVantage specializes in nutrigenomics and offers a range of products including dietary supplements and skin care solutions, while continuously focusing on innovation and growth in this sector.